knowledge -WSS

knowledge

author：explore 2025-09-28 15:21:14 - browse：82269

A sign of Lilly on the top of its biotechnology center — coverage from STAT — Adobe

Eli Lilly reported Thursday that its experimental weekly insulin worked as well as daily basal insulin products in two late-stage studies, paving the way for the drug to compete with a similar weekly insulin developed by Novo Nordisk.

In a 52-week trial of type 2 diabetes patients using insulin for the first time, those on the weekly insulin, called efsitora alfa, had a 1.34% reduction in blood sugar levels, while people on the comparator daily insulin degludec, sold as Tresiba by Novo, had a 1.26% lowering. That resulted in patients having blood sugar levels, known as A1C readings, of 6.87% and 6.95%, respectively.

In a separate 26-week trial of type 2 patients who have been using insulin, those on efsitora and the comparator daily insulin glargine, sold by Lilly as Basaglar and Sanofi as Lantus, both saw A1C reductions of 1.07%, resulting in blood sugar levels of 7.12% and 7.11%, respectively.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： CDC recommends rationing of RSV shot due to shortages

entertainment

WSS

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

Anthos stroke drug appears safer than common blood thinner

Congress must reauthorize a committee to support older Americans

Morphosys mixed study results for blood cancer drug

FDA's Woodcock to retire early next year

The pink breast cancer awareness ribbon needs a redesign

knowledge

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Supreme Court strikes down use of affirmative action

First Opinion Podcast: How to protect health care in times of war

As demand for Covid shots wanes, Moderna seeks its next success

Biden's order seeks to regulate AI risk without stifling innovation

The high cost of giving birth even with insurance

Readout Newsletter: XBI biotech index, Akero Therapeutics

Apple is now the first public company to be valued at $3 trillion

First Opinion Podcast: How to protect health care in times of war

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Does good food count as health care? Study aims to find out

explore

Telehealth options flood the market as retailers push virtual care

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

Readout LOUD podcast: A CRISPR milestone, biotech mixology

CRISPR pioneers react to Casgevy, first gene

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

Morphosys mixed study results for blood cancer drug

hotspot

entertainment

entertainment

leisure time